Pages that link to "Q24802100"
The following pages link to The present and future role of bisphosphonates in the management of patients with breast cancer (Q24802100):
Displaying 12 items.
- Evolution of bisphosphonate-related osteonecrosis of the jaw in patients with multiple myeloma and Waldenstrom's macroglobulinemia: a retrospective multicentric study (Q35865686) (← links)
- Clodronate : a review of its use in the prevention of bone metastases and the management of skeletal complications associated with bone metastases in patients with breast cancer (Q35956623) (← links)
- Health state utilities for skeletal-related events secondary to bone metastases (Q37470069) (← links)
- Epidemiology, clinical manifestations, risk reduction and treatment strategies of jaw osteonecrosis in cancer patients exposed to antiresorptive agents (Q38184580) (← links)
- A short account of metastatic bone disease (Q38255403) (← links)
- Combination of zoledronic acid and serine/threonine phosphatase inhibitors induces synergistic cytotoxicity and apoptosis in human breast cancer cells via inhibition of PI3K/Akt pathway. (Q38828243) (← links)
- Elaborating on efficient anti-proliferation agents of cancer cells and anti-inflammatory-based N-bisphosphonic acids (Q39459827) (← links)
- A pH-sensitive, biobased calcium carbonate aragonite nanocrystal as a novel anticancer delivery system (Q42019484) (← links)
- Once-yearly intravenous zoledronate does not impair renal function in postmenopausal women (Q46425299) (← links)
- Are oral bisphosphonates effective in improving lumbar bone mineral density in breast cancer survivors with osteopenia or osteoporosis? (Q46803164) (← links)
- Antiresorptive treatment-associated ONJ. (Q47732074) (← links)
- Tracking bisphosphonates through a 20 mm thick porcine tissue by using surface-enhanced spatially offset Raman spectroscopy (Q48776627) (← links)